Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Amgen Inc's Business Segments
Amgen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 8,618
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 8,618 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product95.4%
- Other products13.1%
- Repatha (evolocumab)5.4%
- Prolia5.3%
- EVENITY5%
- TEPEZZA4.9%
- Product and Service, Other4.6%
- Otezla4.1%
- TEZSPIRE4%
- ENBREL3.6%
- Nplate3.3%
- KRYSTEXXA3%
- UPLIZNA2.9%
- XGEVA2.6%
- BLINCYTO2.6%
- KYPROLIS2.5%
- IMDELLTRA/IMDYLLTRA2.2%
- Vectibix1.6%
- Aranesp0.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 8,218 | 95.4% |
| Other products | $ 1,131 | 13.1% |
| Repatha (evolocumab) | $ 465 | 5.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
16 more categories available
Sign in to unlock the full Amgen Inc dataset.
Description of Amgen Inc
Business Description of Amgen Inc.
Amgen Inc. is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen specializes in discovering, developing, manufacturing, and marketing innovative human therapeutics, with a strong commitment to advancing biotechnology based on cellular and molecular biology. The company aims to serve patients by focusing on serious illnesses and chronic conditions, with a diverse portfolio of therapies that target areas such as oncology, hematology, cardiovascular disease, neuroscience, and inflammation.
One of Amgen’s key strengths lies in its robust research and development (R&D) efforts, which have positioned the company as a pioneer in biotechnology. Amgen invests heavily in R&D to innovate and refine its biopharmaceutical products, leveraging its expertise in genetic engineering and human biology. The company’s advanced capabilities in protein and antibody development have enabled it to create some of the most transformative treatments in healthcare.
In 2002, Amgen enhanced its market position by acquiring Immunex Corporation, a strategic move that added valuable assets to its portfolio. Immunex was renowned for its focus on immune system science and had developed significant therapies, including the widely used rheumatoid arthritis medication, Enbrel. The integration of Immunex not only broadened Amgens therapeutic offerings but also enriched its capabilities in drug development, particularly in immunology and related fields.
Amgens product portfolio includes several blockbuster drugs, such as Neulasta and Neupogen, which are vital in the treatment of cancer patients undergoing chemotherapy, as well as Osteoporosis treatments like Prolia and Evenity. Additionally, Amgen has made significant strides in the biosimilars market, aiming to provide more affordable, high-quality alternatives to existing biologic therapies.
The company operates with a global presence, with its products available in numerous countries around the world. In addition to traditional biopharmaceuticals, Amgen is investing in new technologies such as gene therapy, cell therapy, and digital health solutions, reflecting a commitment to innovation and improvement in patient care.
Sustainability and corporate responsibility are also important aspects of Amgens operations, as the company aims to contribute positively to society through ethical practices, environmental stewardship, and community engagement initiatives.
With a strong focus on patient needs and scientific innovation, Amgen is poised to continue its leadership role in the biotechnology industry while tackling some of the most pressing health issues facing humanity today. The company’s commitment to advancing biotechnology remains at the forefront of its mission to deliver transformative products that can significantly improve patient outcomes across the globe.
Amgen Inc. is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen specializes in discovering, developing, manufacturing, and marketing innovative human therapeutics, with a strong commitment to advancing biotechnology based on cellular and molecular biology. The company aims to serve patients by focusing on serious illnesses and chronic conditions, with a diverse portfolio of therapies that target areas such as oncology, hematology, cardiovascular disease, neuroscience, and inflammation.
One of Amgen’s key strengths lies in its robust research and development (R&D) efforts, which have positioned the company as a pioneer in biotechnology. Amgen invests heavily in R&D to innovate and refine its biopharmaceutical products, leveraging its expertise in genetic engineering and human biology. The company’s advanced capabilities in protein and antibody development have enabled it to create some of the most transformative treatments in healthcare.
In 2002, Amgen enhanced its market position by acquiring Immunex Corporation, a strategic move that added valuable assets to its portfolio. Immunex was renowned for its focus on immune system science and had developed significant therapies, including the widely used rheumatoid arthritis medication, Enbrel. The integration of Immunex not only broadened Amgens therapeutic offerings but also enriched its capabilities in drug development, particularly in immunology and related fields.
Amgens product portfolio includes several blockbuster drugs, such as Neulasta and Neupogen, which are vital in the treatment of cancer patients undergoing chemotherapy, as well as Osteoporosis treatments like Prolia and Evenity. Additionally, Amgen has made significant strides in the biosimilars market, aiming to provide more affordable, high-quality alternatives to existing biologic therapies.
The company operates with a global presence, with its products available in numerous countries around the world. In addition to traditional biopharmaceuticals, Amgen is investing in new technologies such as gene therapy, cell therapy, and digital health solutions, reflecting a commitment to innovation and improvement in patient care.
Sustainability and corporate responsibility are also important aspects of Amgens operations, as the company aims to contribute positively to society through ethical practices, environmental stewardship, and community engagement initiatives.
With a strong focus on patient needs and scientific innovation, Amgen is poised to continue its leadership role in the biotechnology industry while tackling some of the most pressing health issues facing humanity today. The company’s commitment to advancing biotechnology remains at the forefront of its mission to deliver transformative products that can significantly improve patient outcomes across the globe.
Overview of Amgen Inc.s Segments, Products, and Services
Amgen, Inc. is a biotechnology company renowned for its focus on developing and manufacturing human therapeutics, primarily emphasizing protein-based medications. The companys commitment to biopharmaceutical innovation extends across a variety of therapeutic areas, which include hematology, oncology, inflammation, metabolic disorders, bone health, and neuroscience. Through a robust portfolio of biologics and small molecules, Amgen seeks to address the unmet medical needs of patients across the globe.
Product Lines
1. Erythropoiesis-Stimulating Agents (ESAs):
- EPOGEN® (Epoetin alfa): This recombinant human erythropoietin medication stimulates red blood cell production and is primarily used for treating anemia associated with chronic renal failure, particularly in dialysis patients. EPOGEN® helps elevate hematocrit and hemoglobin levels while reducing the need for blood transfusions, thereby improving the quality of life for patients with anemia.
- Aranesp® (Darbepoetin alfa): A modified form of erythropoietin, Aranesp® has an extended half-life, allowing for less frequent dosing compared to EPOGEN®. It is used to treat anemia in both dialysis and non-dialysis chronic renal failure patients, as well as for chemotherapy-induced anemia.
2. Granulocyte Colony-Stimulating Factors:
- NEUPOGEN® (Filgrastim): This medication stimulates the production of neutrophils, enhancing recovery outcomes in patients experiencing neutropenia due to chemotherapy. It is also instrumental in facilitating the recovery of neutrophils following bone marrow transplantation and can mobilize peripheral blood progenitor cells for transplantation.
- Neulasta® (Pegfilgrastim): A pegylated version of Filgrastim, Neulasta® is designed for single-dose administration per chemotherapy cycle. It provides similar benefits to NEUPOGEN® in reducing the risk of infections associated with chemotherapy-induced neutropenia.
3. Inflammatory Disease Treatments:
- ENBREL® (Etanercept): A fusion protein that inhibits tumor necrosis factor (TNF), ENBREL® is used for treating chronic inflammatory conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. It alleviates symptoms, enhances function, and prevents structural damage to joints.
4. Bone Health:
- Sensipar® (Cinacalcet HCl): Approved for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and for managing hypercalcemia in parathyroid carcinoma patients, Sensipar® acts as a calcimimetic to lower parathyroid hormone levels effectively.
- AMG 162: This monoclonal antibody targets RANKL and inhibits osteoclast-mediated bone resorption. It is currently under investigation for treating postmenopausal osteoporosis and managing bone metastases resulting from various cancers.
5. Oncology:
- Vectibix® (Panitumumab): As the first fully human monoclonal antibody for treating metastatic colorectal cancer with epidermal growth factor receptor (EGFr) expression, Vectibix enhances targeted therapy and significantly reduces the risk of immune response associated with traditional therapies.
- Palifermin: This treatment is under investigation for reducing oral mucositis resulting from chemotherapy and radiation therapy. Clinical studies have shown promising results in minimizing both the incidence and duration of severe mucositis.
6. Metabolic Disorders:
- Amgen is dedicated to innovating therapies for metabolic diseases, including secondary hyperparathyroidism and type 2 diabetes. The development of calcimimetics, which regulate calcium levels effectively through proprietary calcium receptor technology, underscores their ongoing commitment to metabolic health.
Neuroscience:
- Amgen is exploring treatments focused on neurotrophic factors that promote nerve cell protection and regeneration. Current research may lead to insights into therapies for neurodegenerative diseases, although previous projects, such as the development of GDNF for Parkinsons disease, were halted due to insufficient efficacy.
Services
Apart from its pharmaceutical products, Amgen provides a range of support services intended to facilitate patient care and healthcare provider efficacy:
- Patient Assistance Programs: Amgen maintains programs that aim to provide patients with access to medications through various forms of financial support, alongside educational resources that enhance understanding and adherence to prescribed therapies.
- Healthcare Provider Resources: A suite of tools and materials is available for clinicians, which includes dosing guides, safety information, and educational content designed to optimize the prescription and administration of Amgen products.
- Clinical Trials: Amgen actively participates in extensive clinical research to evaluate innovative therapies, investigate combinations, and explore new indications for existing products. This commitment to research is paramount to advancing therapeutic knowledge and improving patient outcomes.
Research and Development Focus
Amgens research and development efforts are principally directed towards creating future therapeutics across hematology, oncology, inflammation, metabolic disorders, bone health, and neuroscience. The company focuses on biologics and monoclonal antibodies, which provide targeted therapies characterized by specificity and reduced side effects when compared to traditional treatments.
In conclusion, Amgen, Inc. continues to advance therapies that enhance the quality of life for patients enduring complex and chronic diseases worldwide. Its dedication to scientific innovation, coupled with an extensive portfolio of therapeutics, secures its position as a leader within the biotechnology landscape.
Amgen, Inc. is a biotechnology company renowned for its focus on developing and manufacturing human therapeutics, primarily emphasizing protein-based medications. The companys commitment to biopharmaceutical innovation extends across a variety of therapeutic areas, which include hematology, oncology, inflammation, metabolic disorders, bone health, and neuroscience. Through a robust portfolio of biologics and small molecules, Amgen seeks to address the unmet medical needs of patients across the globe.
Product Lines
1. Erythropoiesis-Stimulating Agents (ESAs):
- EPOGEN® (Epoetin alfa): This recombinant human erythropoietin medication stimulates red blood cell production and is primarily used for treating anemia associated with chronic renal failure, particularly in dialysis patients. EPOGEN® helps elevate hematocrit and hemoglobin levels while reducing the need for blood transfusions, thereby improving the quality of life for patients with anemia.
- Aranesp® (Darbepoetin alfa): A modified form of erythropoietin, Aranesp® has an extended half-life, allowing for less frequent dosing compared to EPOGEN®. It is used to treat anemia in both dialysis and non-dialysis chronic renal failure patients, as well as for chemotherapy-induced anemia.
2. Granulocyte Colony-Stimulating Factors:
- NEUPOGEN® (Filgrastim): This medication stimulates the production of neutrophils, enhancing recovery outcomes in patients experiencing neutropenia due to chemotherapy. It is also instrumental in facilitating the recovery of neutrophils following bone marrow transplantation and can mobilize peripheral blood progenitor cells for transplantation.
- Neulasta® (Pegfilgrastim): A pegylated version of Filgrastim, Neulasta® is designed for single-dose administration per chemotherapy cycle. It provides similar benefits to NEUPOGEN® in reducing the risk of infections associated with chemotherapy-induced neutropenia.
3. Inflammatory Disease Treatments:
- ENBREL® (Etanercept): A fusion protein that inhibits tumor necrosis factor (TNF), ENBREL® is used for treating chronic inflammatory conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. It alleviates symptoms, enhances function, and prevents structural damage to joints.
4. Bone Health:
- Sensipar® (Cinacalcet HCl): Approved for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and for managing hypercalcemia in parathyroid carcinoma patients, Sensipar® acts as a calcimimetic to lower parathyroid hormone levels effectively.
- AMG 162: This monoclonal antibody targets RANKL and inhibits osteoclast-mediated bone resorption. It is currently under investigation for treating postmenopausal osteoporosis and managing bone metastases resulting from various cancers.
5. Oncology:
- Vectibix® (Panitumumab): As the first fully human monoclonal antibody for treating metastatic colorectal cancer with epidermal growth factor receptor (EGFr) expression, Vectibix enhances targeted therapy and significantly reduces the risk of immune response associated with traditional therapies.
- Palifermin: This treatment is under investigation for reducing oral mucositis resulting from chemotherapy and radiation therapy. Clinical studies have shown promising results in minimizing both the incidence and duration of severe mucositis.
6. Metabolic Disorders:
- Amgen is dedicated to innovating therapies for metabolic diseases, including secondary hyperparathyroidism and type 2 diabetes. The development of calcimimetics, which regulate calcium levels effectively through proprietary calcium receptor technology, underscores their ongoing commitment to metabolic health.
Neuroscience:
- Amgen is exploring treatments focused on neurotrophic factors that promote nerve cell protection and regeneration. Current research may lead to insights into therapies for neurodegenerative diseases, although previous projects, such as the development of GDNF for Parkinsons disease, were halted due to insufficient efficacy.
Services
Apart from its pharmaceutical products, Amgen provides a range of support services intended to facilitate patient care and healthcare provider efficacy:
- Patient Assistance Programs: Amgen maintains programs that aim to provide patients with access to medications through various forms of financial support, alongside educational resources that enhance understanding and adherence to prescribed therapies.
- Healthcare Provider Resources: A suite of tools and materials is available for clinicians, which includes dosing guides, safety information, and educational content designed to optimize the prescription and administration of Amgen products.
- Clinical Trials: Amgen actively participates in extensive clinical research to evaluate innovative therapies, investigate combinations, and explore new indications for existing products. This commitment to research is paramount to advancing therapeutic knowledge and improving patient outcomes.
Research and Development Focus
Amgens research and development efforts are principally directed towards creating future therapeutics across hematology, oncology, inflammation, metabolic disorders, bone health, and neuroscience. The company focuses on biologics and monoclonal antibodies, which provide targeted therapies characterized by specificity and reduced side effects when compared to traditional treatments.
In conclusion, Amgen, Inc. continues to advance therapies that enhance the quality of life for patients enduring complex and chronic diseases worldwide. Its dedication to scientific innovation, coupled with an extensive portfolio of therapeutics, secures its position as a leader within the biotechnology landscape.